Novo Nordisk has completed its acquisition of Dicerna Pharmaceuticals. The company develops mRNA-based drugs and also owns a technology platform to access intracellular disease targets in hepatic and extrahepatic cells and tissues. Novo Nordisk paid $3.3 billion, or $38.25 per Dicerna share.